We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co( II) and Zn( II) compounds.
- Authors
Raposo, L. R.; Roma‐Rodrigues, C.; Jesus, J.; Martins, L. M. D. R. S.; Pombeiro, A. J.; Baptista, P. V.; Fernandes, A. R.
- Abstract
Background Despite continuous efforts, the treatment of canine cancer has still to deliver effective strategies. For example, traditional chemotherapy with doxorubicin and/or docetaxel does not significantly increase survival in dogs with canine mammary tumors (CMTs). Aims Evaluate the efficiency of two metal compounds [Zn(DION)2]Cl (TS262, DION = 1,10-phenanthroline-5,6-dione) and [CoCl(H2O)(DION)2][BF4] (TS265) and novel nanovectorizations designed to improve the anti-cancer efficacy of these compounds in a new CMT derived cell line (FR37-CMT). Materials and methods FR37-CMT cells were exposed to different concentrations of TS262 and TS265 and two new nanoparticle systems and cellular viability was determined. These nanosystems are composed of polyethylene-glycol, bovine-serum-albumin and TS262 or TS265 (NanoTS262 or NanoTS265, respectively). Results In FR37-CMT, TS262 and TS265 displayed IC50 values well below those displayed by doxorubicin and cisplatin. The nanovectorizations further decreased the IC50 values. Discussion TS262 and TS265 proved to be effective against FR37-CMT cells and more effective than of doxorubicin and cisplatin. The Nanosystems efficiently delivered the cytotoxic cargo inducing a significant reduction of cell viability in FR37-CMT cell line when compared to the free compounds. Conclusions TS262 and TS265 are compounds with potential in the treatment of CMTs. NanoTS262 and NanoTS265 demonstrate that such simple nanovectorization via gold nanoparticles shows tremendous potential as anti-cancer formulations, which may easily be expanded to suit other cargo.
- Subjects
MAMMARY gland tumors; GOLD nanoparticles; CANCER in dogs; PHENANTHROLINE; NANOTECHNOLOGY; CISPLATIN; DOXORUBICIN
- Publication
Veterinary & Comparative Oncology, 2017, Vol 15, Issue 4, p1537
- ISSN
1476-5810
- Publication type
Article
- DOI
10.1111/vco.12298